These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23354306)

  • 1. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
    Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
    Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
    Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
    Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
    Gysin S; Paquette J; McMahon M
    Mol Cancer Res; 2012 Dec; 10(12):1607-19. PubMed ID: 22833572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
    Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
    Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
    Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
    Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology and clinical development of MEK inhibitors for cancer.
    Luke JJ; Ott PA; Shapiro GI
    Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibitor for gastric cancer with MEK1 gene mutations.
    Sogabe S; Togashi Y; Kato H; Kogita A; Mizukami T; Sakamoto Y; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Tomida S; Yasuda T; Takeyama Y; Okuno K; Nishio K
    Mol Cancer Ther; 2014 Dec; 13(12):3098-106. PubMed ID: 25253779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
    Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
    Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel changes in NF-{kappa}B activity during progression and regression phases of hyperplasia: role of MEK, ERK, and p38.
    Chandrakesan P; Ahmed I; Anwar T; Wang Y; Sarkar S; Singh P; Peleg S; Umar S
    J Biol Chem; 2010 Oct; 285(43):33485-33498. PubMed ID: 20710027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
    Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
    Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K.
    Kim JE; Lee DE; Lee KW; Son JE; Seo SK; Li J; Jung SK; Heo YS; Mottamal M; Bode AM; Dong Z; Lee HJ
    Cancer Prev Res (Phila); 2011 Apr; 4(4):582-91. PubMed ID: 21330379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.
    Duhamel S; Hébert J; Gaboury L; Bouchard A; Simon R; Sauter G; Basik M; Meloche S
    Cancer Res; 2012 Feb; 72(3):626-35. PubMed ID: 22298595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.